Art

J-GLOBAL ID：201702228266093057   Reference number：17A0087859

Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study

進行性肝細胞癌のための低用量インターフェロン療法と併用したソラフェニブの効果:予備研究

Author (8)： Itokawa Norio (Nippon Medical School Chiba Hokusoh Hospital) ,  Atsukawa Masanori (Nippon Medical School Chiba Hokusoh Hospital) ,  Tsubota Akihito (Jikei University, School of Medicine) ,  Okubo Tomomi (Nippon Medical School Chiba Hokusoh Hospital) ,  Arai Taeang (Nippon Medical School Chiba Hokusoh Hospital) ,  Nakagawa Ai (Nippon Medical School Chiba Hokusoh Hospital) ,  Kondo Chisa (Nippon Medical School Chiba Hokusoh Hospital) ,  Iwakiri Katsuhiko (Nippon Medical School Chiba Hokusoh Hospital)
Material： International Journal of Clinical Oncology  (Int J Clin Oncol)
Volume： 21  Issue： 4  Page： 676-683  Publication year： Aug. 2016 
JST Material Number： L3966A  ISSN： 1341-9625  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *Advanced hepatocellular carcinoma ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0087859&from=J-GLOBAL&jstjournalNo=L3966A") }}

Author keywords (5)： Hepatocellular carcinoma ,  Sorafenib ,  Pegylated interferon ,  Vascular endothelial growth factor ,  α-Fetoprotein

JST classification (2)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Substance index (1)： Sorafenib

Reference (43)：

• Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236
• Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917
• European Association For The Study Of The Liver1, European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines management of hepatocellular carcinoma. J Hepatol 56:908-943
• Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
• Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34

Terms in the title (6)： 進行性肝細胞癌 ,  低用量 ,  インターフェロン療法 ,  併用 ,  ソラフェニブ ,  研究